Amedeo Smart

Free Medical Literature Service



Liver Diseases

  Free Subscription


3 Am J Gastroenterol
2 BMC Cancer
2 BMC Gastroenterol
2 Cancer
3 Cancer Res
1 Dig Dis Sci
2 Endoscopy
2 Eur Radiol
1 Gastroenterology
1 Gastrointest Endosc
1 Gut
20 Hepatology
12 J Hepatol
1 J Pediatr
1 Minerva Gastroenterol (Torino)
1 Oncogene
1 PLoS Comput Biol
1 PLoS One
1 Proc Natl Acad Sci U S A
2 Semin Liver Dis

    Am J Gastroenterol

  1. SERPER M, Tapper EB, Kaplan DE, Taddei TH, et al
    Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the Pandemic.
    Am J Gastroenterol. 2022 Sep 16. pii: 00000434-990000000-00513.
    >> Share

  2. GUPTA A, Rana R, Agarwal S, Sharma S, et al
    Assessing the risk of further decompensation and survival in patients with cirrhosis with variceal bleeding as their first decompensation event.
    Am J Gastroenterol. 2022 Sep 16. pii: 00000434-990000000-00510.
    >> Share

  3. SINGAL AG, Reig M, Villanueva A
    Emerging Tools for Hepatocellular Carcinoma Surveillance.
    Am J Gastroenterol. 2022 Sep 16. pii: 00000434-990000000-00505.
    >> Share

    BMC Cancer

  4. FANG G, Zhang Q, Fan J, Li H, et al
    Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.
    BMC Cancer. 2022;22:999.
    >> Share

  5. PARK BC, Lee AXT, Ye F, Turker I, et al
    Immune checkpoint inhibitors and their impact on liver enzymes and attenuation.
    BMC Cancer. 2022;22:998.
    >> Share

    BMC Gastroenterol

  6. WANG X, Han Y, Liu Y, Hu H, et al
    Association between serum uric acid-to-creatinine ratio and non-alcoholic fatty liver disease: a cross-sectional study in Chinese non-obese people with a normal range of low-density lipoprotein cholesterol.
    BMC Gastroenterol. 2022;22:419.
    >> Share

  7. CHANG SS, Hu HY, Chen YC, Yen YF, et al
    Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case-control study.
    BMC Gastroenterol. 2022;22:425.
    >> Share


  8. LI Y, Liang X, Li H, Chen X, et al
    Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Cancer. 2022 Sep 16. doi: 10.1002/cncr.34457.
    >> Share

  9. MATTINGLY TJ 2ND, Shetty K
    The economics of advanced and unresectable hepatocellular carcinoma.
    Cancer. 2022 Sep 15. doi: 10.1002/cncr.34456.
    >> Share

    Cancer Res

  10. XIAO Y, Li Y, Shi D, Wang X, et al
    MEX3C-mediated decay of SOCS3 mRNA promotes JAK2/STAT3 signaling to facilitate metastasis in hepatocellular carcinoma.
    Cancer Res. 2022 Sep 16. pii: 709244. doi: 10.1158/0008-5472.CAN-22-1203.
    >> Share

  11. MAN K, Pang L, Yeung OWH, Ng KTP, et al
    Postoperative plasmacytoid dendritic cells secrete IFN-alpha to promote recruitment of myeloid-derived suppressor cells and drive hepatocellular carcinoma recurrence.
    Cancer Res. 2022 Sep 14. pii: 709225. doi: 10.1158/0008-5472.CAN-22-1199.
    >> Share

  12. HUANG M, Long J, Yao Z, Zhao Y, et al
    METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma.
    Cancer Res. 2022 Sep 14. pii: 709196. doi: 10.1158/0008-5472.CAN-22-0963.
    >> Share

    Dig Dis Sci

  13. HARTGERINK C, Nimri FM, Zuchelli T, Jafri SM, et al
    Band Ligation Can Be Used to Treat Barrett's Esophagus and Concurrent Esophageal Varices: A Case Series.
    Dig Dis Sci. 2022 Sep 21. pii: 10.1007/s10620-022-07696.
    >> Share


  14. HIJIOKA S, Sakamoto Y, Nagashio Y, Maruki Y, et al
    Novel and safe plastic stent exchange method after endoscopic ultrasound-guided hepaticogastrostomy with incomplete fistula (side hole method).
    Endoscopy. 2022 Sep 16. doi: 10.1055/a-1930-6319.
    >> Share

  15. YANG W, Ye L, Tang C, Hu B, et al
    Peroral endoscopic myotomy after transjugular intrahepatic portosystemic shunt and variceal embolization for a patient with achalasia and esophageal varices.
    Endoscopy. 2022 Sep 16. doi: 10.1055/a-1929-9364.
    >> Share

    Eur Radiol

  16. LIU K, Zheng H, Sui X, Liu B, et al
    Microwave ablation versus surgical resection for subcapsular hepatocellular carcinoma: a propensity score-matched study of long-term therapeutic outcomes.
    Eur Radiol. 2022 Sep 17. pii: 10.1007/s00330-022-09135.
    >> Share

  17. XIAO Y, Zheng X, Zhou C, Huang P, et al
    Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.
    Eur Radiol. 2022 Sep 16. pii: 10.1007/s00330-022-09131.
    >> Share


  18. HABER PK, Castet F, Torres-Martin M, Andreu-Oller C, et al
    Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
    Gastroenterology. 2022 Sep 12. pii: S0016-5085(22)01039.
    >> Share

    Gastrointest Endosc

    Sedation during EUS-guided portal pressure gradient measurement: the elephant in the room.
    Gastrointest Endosc. 2022;96:690-691.
    >> Share


  20. KULKARNI AV, Metage CS, Gora BA, Tirumalle S, et al
    SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis.
    Gut. 2022 Sep 16. pii: gutjnl-2022-328451. doi: 10.1136/gutjnl-2022-328451.
    >> Share


  21. LIU Y, Zhang J, Xu Y, Lu X, et al
    Letter to the editor: Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients.
    Hepatology. 2022 Sep 14. doi: 10.1002/hep.32785.
    >> Share

  22. CHEN YT, Su YC, Or YE, Cheng CF, et al
    CD8(+) T cell memory is sustained in mice by hepatic stellate cells.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32788.
    >> Share

  23. MAO X, Cheung KS, Peng C, Mak LY, et al
    Steatosis, HBV-related hepatocellular carcinoma, cirrhosis & HBsAg seroclearance: a systematic review and meta-analysis.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32792.
    >> Share

  24. JACHS M, Tillmann HL
    Editorial: It's not all about the virus - on the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B.
    Hepatology. 2022 Sep 17. doi: 10.1002/hep.32798.
    >> Share

  25. MANNA D, Reghupaty SC, Camarena MDC, Mendoza RG, et al
    Melanoma Differentiation Associated Gene-9/Syndecan Binding Protein (MDA-9/SDCBP) Promotes Hepatocellular Carcinoma (HCC).
    Hepatology. 2022 Sep 19. doi: 10.1002/hep.32797.
    >> Share

  26. GAMBINO C, Piano S, Stenico M, Tonon M, et al
    Diagnostic and prognostic performance of urinary Neutrophil Gelatinase-associated Lipocalin in patients with cirrhosis and AKI.
    Hepatology. 2022 Sep 20. doi: 10.1002/hep.32799.
    >> Share

  27. MAK LY, Hui RW, Lee CH, Mao X, et al
    Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.
    Hepatology. 2022 Sep 21. doi: 10.1002/hep.32716.
    >> Share

  28. WANG H, Zhou Y, Xu H, Wang X, et al
    Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
    Hepatology. 2022;76:951-966.
    >> Share

  29. BAPTISSART M, Bradish CM, Jones BS, Walsh E, et al
    Zac1 and the Imprinted Gene Network program juvenile NAFLD in response to maternal metabolic syndrome.
    Hepatology. 2022;76:1090-1104.
    >> Share

  30. WANG H, Zhang B, Li R, Chen J, et al
    KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration.
    Hepatology. 2022;76:967-981.
    >> Share

  31. SONG L, Wang L, Hou Y, Zhou J, et al
    FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis.
    Hepatology. 2022;76:1105-1120.
    >> Share

  32. KARL M, Hasselwander S, Zhou Y, Reifenberg G, et al
    Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease.
    Hepatology. 2022;76:1135-1149.
    >> Share

  33. MARTINEZ-ARRANZ I, Bruzzone C, Noureddin M, Gil-Redondo R, et al
    Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.
    Hepatology. 2022;76:1121-1134.
    >> Share

  34. LASCHTOWITZ A, Tacke F
    Many roads lead to Rome: The FGF4-AMP-activated protein kinase-Caspase 6 signal axis in NAFLD and NASH.
    Hepatology. 2022;76:911-913.
    >> Share

  35. PAI RK, Jairath V, Hogan M, Zou G, et al
    Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.
    Hepatology. 2022;76:1150-1163.
    >> Share

  36. BARROW F, Revelo XS
    The B side of B cells in NAFLD.
    Hepatology. 2022;76:914-916.
    >> Share

  37. DEVARBHAVI H, Kurien SS
    Letter to the editor: A revised electronic version of RUCAM for the diagnosis of drug-induced liver injury.
    Hepatology. 2022;76:E71-E72.
    >> Share

  38. SUCHMAN K, Da BL
    Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC.
    Hepatology. 2022;76:E78-E79.
    >> Share

  39. AHMAD A
    Letter to the Editor: The Precise Relationship Between MELD and Survival Without a Liver Transplant.
    Hepatology. 2022 Jun 11. doi: 10.1002/hep.32602.
    >> Share

  40. WU T, Povero D, Parthasarathy G, Idalsoaga F, et al
    Hepatology highlights.
    Hepatology. 2022;76:901-902.
    >> Share

    J Hepatol

  41. MARTIN-NAVARRO L, de Andrea C, Sangro B, Argemi J, et al
    In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID19 vaccine-related hepatitis.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03076.
    >> Share

  42. ZANETTO A, Pelizzaro F, Campello E, Bulato C, et al
    Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03110.
    >> Share

  43. ARECHEDERRA M, Fernandez-Barrena MG
    Hepatic progenitor cells, senescence and IL6 as the main players in combined hepatocellular-cholangiocarcinoma development.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03114.
    >> Share

  44. RIDOLA L, Riggio O
    Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03112.
    >> Share

  45. BASTATI N, Beer L, Ba-Ssalamah A, Poetter-Lang S, et al
    Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD.
    J Hepatol. 2022;77:1005-1013.
    >> Share

  46. BHAGAT N, Verma N, Singh V
    HCC prediction post SVR in HCV patients: many tools yet limited generalizability!
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00264.
    >> Share

  47. STAUFER K, Huber-Schonauer U, Strebinger G, Pimingstorfer P, et al
    Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.
    J Hepatol. 2022;77:918-930.
    >> Share

  48. VAN KLEEF LA, Lu Z, Arfan Ikram M, de Groot NMS, et al
    Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam study.
    J Hepatol. 2022;77:931-938.
    >> Share

  49. DE GOTTARDI A, Sempoux C, Berzigotti A
    Porto-sinusoidal vascular disorder.
    J Hepatol. 2022;77:1124-1135.
    >> Share

  50. EASL Clinical Practice Guidelines on the management of cystic liver diseases.
    J Hepatol. 2022;77:1083-1108.
    >> Share

  51. PEISELER M, Schwabe R, Hampe J, Kubes P, et al
    Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
    J Hepatol. 2022;77:1136-1160.
    >> Share

  52. BITTENCOURT PL, Oliveira CP, Codes L, Ferraz MLG, et al
    Internet search engines and social media are improving awareness on non-alcoholic fatty liver disease in Brazil.
    J Hepatol. 2022;77:1217-1219.
    >> Share

    J Pediatr

    50 Years Ago in TheJournalofPediatrics: Understanding Progressive Cholestatic Liver Disease.
    J Pediatr. 2022;248:58.
    >> Share

    Minerva Gastroenterol (Torino)

  54. XIE F, Hong Y, Sun X, Wang B, et al
    Comparison of the value of conventional two-dimensional ultrasound, contrast-enhanced ultrasound and MSCT in early diagnosis of small hepatocellular carcinoma.
    Minerva Gastroenterol (Torino). 2022 Sep 23. pii: S2724-5985.22.03258.
    >> Share


  55. DISKIN B, Adam S, Soto GS, Liria M, et al
    BTLA(+)CD200(+) B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer.
    Oncogene. 2022;41:4349-4360.
    >> Share

    PLoS Comput Biol

  56. SUTER P, Dazert E, Kuipers J, Ng CKY, et al
    Multi-omics subtyping of hepatocellular carcinoma patients using a Bayesian network mixture model.
    PLoS Comput Biol. 2022;18:e1009767.
    >> Share

    PLoS One

  57. LEE J, Park SB, Byun S, Kim HI, et al
    Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance.
    PLoS One. 2022;17:e0274747.
    >> Share

    Proc Natl Acad Sci U S A

  58. LIU F, Gai X, Wu Y, Zhang B, et al
    Oncogenic beta-catenin stimulation of AKT2-CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2202157119.
    >> Share

    Semin Liver Dis

  59. GALA K, Abdul Razzak F, Rapaka B, Dayyeh Bk A, et al
    Novel Endoscopic Bariatric Therapies for the Management of Non-Alcoholic Steatohepatitis.
    Semin Liver Dis. 2022 Sep 18. doi: 10.1055/a-1946-6285.
    >> Share

  60. RASHA F, Paul S, Simon TG, Hoshida Y, et al
    Hepatocellular carcinoma chemoprevention with generic agents.
    Semin Liver Dis. 2022 Sep 14. doi: 10.1055/a-1942-6693.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016